上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2023 , Vol. 43 >Issue 9: 1071 - 1079

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.09.001

论著 · 基础研究

BRCA1 R1325K突变对胆囊癌细胞增殖及凋亡的影响

  • 杨婧潇 ,
  • 贾子尧 ,
  • 吴文广 ,
  • 吴向嵩 ,
  • 张飞 ,
  • 李怀峰 ,
  • 朱逸荻 ,
  • 李茂岚
展开
  • 1.上海交通大学医学院附属仁济医院胆胰外科，上海 200127
    2.上海交通大学医学院附属新华医院普外科，上海 200092
    3.上海市胆道疾病研究中心，上海 200092
杨婧潇（1998—），女，硕士生；电子信箱：yang_jingxiao@126.com。
李茂岚，电子信箱：limaolan6@163.com。

收稿日期: 2023-01-03

  录用日期: 2023-08-29

  网络出版日期: 2023-09-28

基金资助

国家重点研发计划(2021YFE0203300);国家自然科学基金面上项目(82073206);上海市卫生健康委员会健康产业临床研究专项(20224Z0014);上海市教育委员会曙光项目(20SG14);上海市科学技术委员会基础研究项目(20JC1419100);上海市申康医院发展中心临床科技创新项目(SHDC12019110);上海市消化疾病临床医学研究中心分中心(19MC1910200);上海交通大学医学院“双百人”项目(20181808)

收起

Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells

  • Jingxiao YANG ,
  • Ziyao JIA ,
  • Wenguang WU ,
  • Xiangsong WU ,
  • Fei ZHANG ,
  • Huaifeng LI ,
  • Yidi ZHU ,
  • Maolan LI
Expand
  • 1.Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    3.Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China
Li Maolan, E-mail: limaolan6@163.com.

Received date: 2023-01-03

  Accepted date: 2023-08-29

  Online published: 2023-09-28

Supported by

National Key Research and Development Program of China(2021YFE0203300);National Natural Science Foundation of China(82073206);Shanghai Municipal Health Commission Health Industry Clinical Research Special Project(20224Z0014);Shuguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission(20SG14);Basic Research Project of Science and Technology Commission of Shanghai Municipality(20JC1419100);Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center(SHDC12019110);Shanghai Clinical Medical Research Center for Digestive Diseases(19MC1910200);“Two-hundred Talents” Program of Shanghai Jiao Tong University School of Medicine(20181808)

Fold

摘要

目的·探究乳腺癌易感基因1（breast cancer susceptibility gene 1，BRCA1）第1325位精氨酸变为赖氨酸（R1325K突变）对胆囊癌细胞系GBC-SD和NOZ增殖和凋亡的影响。方法·使用BRCA1野生型过表达慢病毒、BRCA1 R1325K突变过表达慢病毒以及阴性对照慢病毒载体构建胆囊癌细胞系GBC-SD和NOZ稳转株。细胞分为不含目的基因的对照组、BRCA1野生型组及BRCA1突变组，并通过Western blotting验证目的蛋白BRCA1的表达情况。选用针对BRCA1突变的抑制剂奥拉帕利（Olaparib）20 μmol/L处理BRCA1突变组胆囊癌细胞，并根据目的蛋白的表达情况和加药与否将胆囊癌细胞系分为对照组、BRCA1野生型组、BRCA1突变组和BRCA1突变+Olaparib组。通过CCK8实验和克隆形成实验观察BRCA1 R1325K突变对胆囊癌细胞系GBC-SD和NOZ增殖能力及克隆形成能力的影响，通过TUNEL实验观察BRCA1 R1325K突变对胆囊癌细胞系GBC-SD和NOZ凋亡情况的影响，并通过Western blotting检测凋亡相关蛋白cleaved PARP、Bcl-2和Bax的表达情况。使用抑制剂Olaparib处理BRCA1 R1325K突变过表达胆囊癌细胞系GBC-SD和NOZ，并检测BRCA1 R1325K突变引起的相应表型改变（促进增殖、增强克隆形成能力和抑制凋亡）是否能被抑制剂所逆转。结果·通过CCK8实验和克隆形成实验发现：相较于对照组及BRCA1野生型组，BRCA1 R1325K突变能够促进胆囊癌细胞系GBC-SD和NOZ的增殖，并提高其克隆形成能力；抑制剂Olaparib处理则能够抑制BRCA1突变胆囊癌细胞系的增殖（均P<0.05）。通过TUNEL和Western blotting实验发现：相较于对照组，野生型BRCA1基因过表达能够诱导胆囊癌细胞系GBC-SD和NOZ的凋亡；BRCA1突变组相较于对照组和BRCA1野生型组，有抵抗凋亡的作用，且升高了凋亡抑制蛋白Bcl-2的表达并降低了促凋亡蛋白Bax的表达（P<0.05）。结论·BRCA1 R1325K突变能够促进胆囊癌细胞系GBC-SD和NOZ的增殖并抑制其凋亡。

关键词： 胆囊癌; BRCA1; 突变; 增殖; 凋亡

本文引用格式

杨婧潇 , 贾子尧 , 吴文广 , 吴向嵩 , 张飞 , 李怀峰 , 朱逸荻 , 李茂岚 . BRCA1 R1325K突变对胆囊癌细胞增殖及凋亡的影响[J]. 上海交通大学学报（医学版）, 2023 , 43(9) : 1071 -1079 . DOI: 10.3969/j.issn.1674-8115.2023.09.001

Abstract

Objective ·To investigate the effects of breast cancer susceptibility gene 1 (BRCA1) R1325K mutation [arginine (R) to lysine (K) mutation at amino acid 1325] on the proliferation and apoptosis of gallbladder cancer cell lines GBC-SD and NOZ. Methods ·BRCA1 wild-type overexpression lentivirus, BRCA1 R1325K mutation overexpression lentivirus, and negative control lentivirus were used to construct the stable transgenic strains of gallbladder carcinoma, cell lines GBC-SD and NOZ. The cells were divided into the control group without the target gene, the BRCA1 wild-type group, and the BRCA1 R1325K mutation group. The expression of target protein was verified by Western blotting. The BRCA1 R1325K mutant gallbladder cancer cells were treated with 20 μmol/L Olaparib, a BRCA1 mutation inhibitor. Gallbladder cancer cell lines were divided into the control group, the BRCA1 wild-type group, the BRCA1 R1325K mutation group, and the BRCA1 R1325K mutation+Olaparib group according to the target gene expression and whether or not the inhibitor was added. The effect of BRCA1 R1325K mutation on proliferation and clonogenesis ability of gallbladder cancer cell lines GBC-SD and NOZ was observed by CCK8 assay and clonogenesis assay, respectively. The effect of BRCA1 R1325K mutation on apoptosis of gallbladder cancer cell lines GBC-SD and NOZ was observed by TUNEL assay. The expressions of apoptosis-related proteins, cleaved PARP, Bcl-2 and Bax, were detected by Western blotting. The inhibitor Olaparib was used to treat the BRCA1 R1325K mutant gallbladder cancer cell lines GBC-SD and NOZ. The phenotypic changes (promoting proliferation, enhancing clonogenesis and inhibiting apoptosis) induced by BRCA1 R1325K mutation were tested in the presence of Olaparib to determine whether the changes could be reversed by the inhibitor. Results ·The results of CCK8 assay and clonogenesis assay showed that BRCA1 R1325K mutation could promote the proliferation of gallbladder cancer cell lines GBC-SD and NOZ, and improve their clonal formation ability, compared with the control group and the BRCA1 wild-type group. Olaparib inhibited the proliferation of gallbladder cancer cell lines overexpressing BRCA1 R1325K mutation (P<0.05). Through TUNEL and Western blotting, it was found that overexpression of wild-type BRCA1 could induce the apoptosis of gallbladder cancer cell lines GBC-SD and NOZ, compared with the control group. Compared with the control group and the BRCA1 wild-type group, the BRCA1 R1325K mutation group had anti-apoptotic effect, in which the expression of apoptosis-inhibiting protein Bcl-2 increased and the expression of pro-apoptotic protein Bax decreased (P<0.05). Conclusion ·BRCA1 R1325K mutation can promote the proliferation of GBC-SD and NOZ cell lines and inhibit their apoptosis.

Key words： gallbladder cancer; BRCA1; mutation; proliferation; apoptosis

参考文献

1 SCHMIDT M A, MARCANO-BONILLA L, ROBERTS L R. Gallbladder cancer: epidemiology and genetic risk associations[J]. Chin Clin Oncol, 2019, 8(4): 31.
2 BAIU I, VISSER B. Gallbladder cancer[J]. JAMA, 2018, 320(12): 1294.
3 MIRANDA-FILHO A, PI?EROS M, FERRECCIO C, et al. Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends[J]. Int J Cancer, 2020, 147(4): 978-989.
4 SHARMA A, SHARMA K L, GUPTA A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update[J]. World J Gastroenterol, 2017, 23(22): 3978-3998.
5 LAMARCA A, EDELINE J, MCNAMARA M G, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020, 84: 101936.
6 ROA J C, GARCíA P, KAPOOR V K, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8: 69.
7 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249.
8 YOSHIDA K, MIKI Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage[J]. Cancer Sci, 2004, 95(11): 866-871.
9 NA R, ZHENG S L, HAN M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death[J]. Eur Urol, 2017, 71(5): 740-747.
10 JOHANNSSON O, LOMAN N, M?LLER T, et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers[J]. Eur J Cancer, 1999, 35(8): 1248-1257.
11 YEHIA L, KEEL E, ENG C. The clinical spectrum of PTEN mutations[J]. Annu Rev Med, 2020, 71: 103-116.
12 WOOSTER R, WEBER B L. Breast and ovarian cancer[J]. N Engl J Med, 2003, 348(23): 2339-2347.
13 NAROD S A. Which genes for hereditary breast cancer?[J]. N Engl J Med, 2021, 384(5): 471-473.
14 DANENBERG E, BARDWELL H, ZANOTELLI V R T, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome[J]. Nat Genet, 2022, 54(5): 660-669.
15 KONSTANTINOPOULOS P A, NORQUIST B, LACCHETTI C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38(11): 1222-1245.
16 SUN S X, BRAZHNIK K, LEE M, et al. Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers[J]. J Clin Invest, 2022, 132(5): e148113.
17 FEILOTTER H E, MICHEL C, UY P, et al. BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development[J]. PLoS One, 2014, 9(6): e100068.
18 WERNER H. BRCA1: an endocrine and metabolic regulator[J]. Front Endocrinol (Lausanne), 2022, 13: 844575.
19 MOSCHETTA M, GEORGE A, KAYE S B, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer[J]. Ann Oncol, 2016, 27(8): 1449-1455.
20 FARMER H, MCCABE N, LORD C J, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005, 434(7035): 917-921.
21 HARKIN DP, BEAN JM, MIKLOS D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1[J]. Cell, 1999, 97(5): 575-586.
22 PAPADAKI C, TSAROUCHA E, KAKLAMANIS L, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer[J]. Br J Cancer, 2011, 104(2): 316-323.
23 BUSACCA S, SHEAFF M, ARTHUR K, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma[J]. J Pathol, 2012, 227(2): 200-208.
24 DEVICO MARCIANO N, KROENING G, DAYYANI F, et al. BRCA-mutated pancreatic cancer: from discovery to novel treatment paradigms[J]. Cancers, 2022, 14(10): 2453.
25 DE BONO J, MATEO J, FIZAZI K, et al. Olaparib for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 382(22): 2091-2102.
26 GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327.
27 MOORE K, COLOMBO N, SCAMBIA G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018, 379(26): 2495-2505.
28 HUSSAIN M, MATEO J, FIZAZI K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 383(24): 2345-2357.
29 ROBSON M E, TUNG N, CONTE P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician′s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019, 30(4): 558-566.
30 XIE Y, JIANG Y, YANG X B, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report[J]. World J Gastroenterol, 2016, 22(46): 10254-10259.
31 LI X F, GAO L M, QIU M, et al. Olaparib treatment in a patient with advanced gallbladder cancer harboring BRCA1 mutation[J]. Onco Targets Ther, 2021, 14: 2815-2819.
32 OUCHI T, MONTEIRO A N, AUGUST A, et al. BRCA1 regulates p53-dependent gene expression[J]. Proc Natl Acad Sci USA, 1998, 95(5): 2302-2306.
33 ZHANG L, ZHOU Q, QIU Q Z, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer[J]. Mol Cancer, 2019, 18(1): 144.
34 LIU X L, LIU H X, ZENG L, et al. BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway[J]. PeerJ, 2022, 10: e14052.
35 MIYASHITA T, KRAJEWSKI S, KRAJEWSKA M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo[J]. Oncogene, 1994, 9(6): 1799-1805.
36 MIYASHITA T, HARIGAI M, HANADA M, et al. Identification of a p53-dependent negative response element in the Bcl-2 gene[J]. Cancer Res, 1994, 54(12): 3131-3135.
37 RESHI L, WU H C, WU J L, et al. GSIV serine/threonine kinase can induce apoptotic cell death via p53 and pro-apoptotic gene Bax upregulation in fish cells[J]. Apoptosis, 2016, 21(4): 443-458.
38 DASHZEVEG N, YOSHIDA K. Cell death decision by p53 via control of the mitochondrial membrane[J]. Cancer Lett, 2015, 367(2): 108-112.
39 LAYANI-BAZAR A, SKORNICK I, BERREBI A, et al. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state[J]. Cancer Res, 2014, 74(11): 3092-3103.
Options
文章导航

/

〈 〉